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idiopathic restless legs syndrome (RLS) has a genetic basis wherein BTBD9 is associated with a 
higher risk of RLS. Hemodialysis patients also exhibit higher rates of RLS compared with the healthy 
population. However, little is known about the relationship of BTBD9 and end-stage renal disease to 
RLS pathophysiology. Here we evaluated sleep and leg muscle activity of Btbd9 mutant (Mt) mice 
after administration of serum from patients with either idiopathic or RLS due to end-stage renal 
disease (renal RLS) and investigated the efficacy of treatment with the dopamine agonist rotigotine. At 
baseline, the amount of rapid eye movement (REM) sleep was decreased and leg muscle activity during 
non-REM (NREM) sleep was increased in MT mice compared to wild-type (WT) mice. Wake-promoting 
effects of rotigotine were attenuated by injection of serum from RLS patients in both WT and MT mice. 
Leg muscle activity during nReM sleep was increased only in Mt mice injected with serum from RLS 
patients of ideiopatic and renal RLS. Subsequent treatment with rotigotine ameliorated this altered 
leg muscle activity. Together these results support previous reports showing a relationship between the 
Btbd9/dopamine system and RLS, and elucidate in part the pathophysiology of RLS.
Restless legs syndrome (RLS) is a common sensorimotor disorder, whose basic components include a sensory 
experience, akathisia, and a sleep-related motor sign, periodic leg movements during sleep (PLMS), both asso-
ciated with an enhancement of the individual’s arousal state1. Although the detailed pathological mechanisms of 
RLS are unclear, RLS occurs in an idiopathic form of genetic origin. Variants in BTBD9, MEIS1, MAP2K5/SKOR1, 
and PTPRD are known to confer a significant risk for RLS2–5. The most common conditions associated with RLS 
include iron deficiency, renal failure, neuropathy, spinal cord pathology, pregnancy, and multiple sclerosis. The 
use of certain medications, including selective serotonin reuptake inhibitors, lithium, dopamine antagonists, and 
caffeine can also increase the rate of RLS6–8. Patients with end stage renal disease (ESRD) receiving hemodialysis 
also have a remarkably higher incidence of RLS relative to the healthy population9,10.
Non-medication therapies such as iron supplementation and life guidance and drug therapies involving dopa-
mine agonists have been widely used to treat RLS. Dopamine therapies have also been reported to be effective in 
treating RLS symptoms associated with chronic kidney disease9,11,12. Rotigotine, a non-ergot dopamine agonist 
that stimulates all dopamine receptor subtype (D1-D5), is approved for the symptomatic treatment of moderate 
to severe idiopathic RLS13. In a rat model of RLS caused by lesioning of dopaminergic nuclei, exposure to the 
neurotoxin 6-hydroxydopamine (6-OHDA) prevented increases in the frequency of limb movement14, whereas 
treatment with the dopaminergic agonist pramipexole decreased limb movement frequency14, suggesting that the 
dopamine system is involved in pathological mechanisms associated with RLS.
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BTBD9 encodes a protein that has two highly conversed domains, the BTB/POZ domain and the BACK 
domain, which are both associated with transcriptional regulation and protein ubiquitination. In humans, a 
genome-wide association (GWAS) study indicated that individuals carrying BTBD9 variants have increased risk 
of familial RLS3. BTBD9 variants are also associated with RLS in ESRD15, although another study reported dif-
fering results9. In animal models of RLS, Btbd9 mutant mice exhibited an increased travel distance in an open 
field test and an increased amount of voluntary activity in a wheel running analysis during the rest phase; these 
changes were accompanied by altered serum iron levels16. In Drosophila, loss of the BTBD9 homolog CG1826 
(dBTBD9) resulted in sleep fragmentation and increased motor activity17. The same report indicated that BTBD9 
controls dopamine levels in fly brains and iron homeostasis in human cell lines17. However, little is known about 
the physiological function of BTBD9 and its relationship to RLS pathophysiology18,19. In particular, how BTBD9 
is associated with RLS that frequently occurs in hemodialysis patients is unclear. We also used a mouse model to 
examine how genetic mutations such as those occurring in BTBD9 contribute to the exacerbation of RLS symp-
toms and whether these symptoms are ameliorated by rotigotine. We also injected wild-type (WT) and Btbd9 
mutant (MT) mice with serum from RLS patients with and without renal involvement who had and had not 
undergone hemodialysis to examine whether substances in RLS patient serum affect response of RLS symptoms 
to rotigotine.
Results
Confirmation of Btbd9 mRNA expression in mutant mice brain. No mRNA expression of Btbd9 
was detected by reverse transcription polymerase chain reaction (RT-PCR) assay based on total RNA extracted 
from mice prefrontal cortex. On the other hand, WT mRNA expression of Btbd9 was amplified obviously 
(Supplementary Fig. S1).
Sleep at baseline and after sleep deprivation (SD). The amounts of wakefulness and non-rapid eye 
movement (NREM) sleep observed for Btbd9 MT mice were similar to those for WT mice (Fig. 1a,b), but the 
amount of rapid eye movement (REM) sleep was decreased compared with that of WT mice in the latter half of 
the light phase (Fig. 1c). MT mice showed increased slow-wave activity (SWA) in NREM sleep, and decreased 
electroencephalogram (EEG) theta power in REM sleep (Fig. 1d,e).
To evaluate sleep homeostasis, mice were sleep-deprived (SD) for 6 hours. During the recovery period after 
SD, both WT and MT mice showed increased SWA in NREM sleep (Fig. 1f).
Figure 1. Sleep/wake patterns in Btbd9 mutant (MT) mice at baseline. Hourly time course (left panels) and 
6-hour bins (right panels; ZT0-6 (L1), ZT6-12 (L2), ZT12-18 (D1) and ZT18-24 (D2)) for (a) wakefulness; (b) 
Non-rapid eye movement (NREM) sleep; (c) Rapid eye movement (REM) sleep; (d) Slow-wave activity (SWA) 
in NREM sleep; (e) Theta power in REM sleep; (f) Rebound response of SWA after 6-hour sleep deprivation 
(SD); Blue circles and bars indicate wild-type (WT) mice, and red circles and bars indicate MT mice. All data 
are expressed as the means ± SEM (n = 6/group). *p < 0.05, WT versus MT mice. SEM, standard error of the 
mean.
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Baseline electromyogram (EMG). In a comparison of representative waveforms of EEG/EMG for WT 
(Fig. 2a) and MT (Fig. 2b) mice, EMG data for gastrocnemius muscle from MT mice indicated increased leg 
muscle activity during NREM sleep compared with WT mice (Fig. 2d), whereas leg muscle activity during wake-
fulness was similar for the two genotypes (Fig. 2c).
Effect of rotigotine on sleep in mice injected with serum from five RLS patients. Next, we 
examined the effect of the dopamine agonist rotigotine (1 and 3 mg/kg, sc) on sleep and muscle activity in mice 
injected with serum from five RLS patients (Supplementary Table 1). Rotigotine treatment increased the amount 
of wakefulness and decreased the amount of NREM sleep in both WT and MT mice injected with placebo saline 
(Figs 3a,e and 4a,b; Supplementary Fig. S2a,e). In WT and MT mice injected with serum from healthy subjects, 
rotigotine treatment also increased the amount of wakefulness and decreased the amount NREM sleep, although 
the effect of rotigotine in MT mice was smaller than that for the WT mice (Figs 3b,f and 4a,b; Supplementary 
Fig. S2b,f). However, mice injected with serum from RLS patients who did or did not undergo hemodialysis did 
not exhibit a wakefulness-promoting effect of rotigotine (Figs 3c,d,g,h and 4a,b; Supplementary Fig. S2c,d,g,h).
The high-dose rotigotine treatment (3 mg/kg, sc) decreased the amount of REM sleep during the light phase in 
WT mice injected with placebo and serum from healthy subjects, and increased the amount of REM sleep during 
the dark phase (Figs 4c and 5a,b). In MT mice injected with placebo and serum from healthy subjects, low-dose 
rotigotine treatment (1 mg/kg, sc) slightly increased the amount of REM sleep during the light phase compared 
with vehicle and high-dose rotigotine (Fig. 4c and 5e,f). Meanwhile, rotigotine did not affect the amount of REM 
sleep in mice injected with serum from RLS patients with or without hemodialysis (Fig. 4c and 5c,d,g,h).
Dopamine agonists targeting the dopamine D3 receptor subtype have a higher efficacy on periodic leg move-
ments and RLS than a drug that preferentially targets the D2 receptor subtype20. These results indicate that serum 
from an RLS patient diminished the wake-promoting effect of rotigotine treatment in mice. However, the influ-
ence of dopamine D2/D3 agonist to sleep structure, human studies will be necessary in the future.
Effect of rotigotine on muscle activity during NREM sleep in mice injected with serum from five 
RLS patients. Leg movement measured by EMG during NREM sleep was increased in MT mice injected 
with serum from RLS patients with or without hemodialysis (Fig. 6). In mice treated with rotigotine after serum 
injection, the amount of leg movement decreased for mice treated with serum from patients who either did or 
did not undergo hemodialysis. These results suggest that serum from five RLS patients can increase leg muscle 
activity during NREM sleep in MT mice, and that rotigotine treatment ameliorates this effect.
Discussion
To our knowledge, this is the first study to measure changes in sleep conditions and periodic limb movements in 
sleep (PLMS) in an animal model of RLS in a related genetic background after administration of serum from a 
patient with severe chronic kidney disease and to assess the effects of a dopamine-receptor agonist on PLMS in 
these animals. In baseline sleep recordings, the amounts of wakefulness and NREM sleep of MT and WT mice 
were similar, whereas the amount of REM sleep was decreased for MT mice relative to WT mice. Reportedly, RLS 
Figure 2. Leg muscle activity during non-rapid eye movement (NREM) sleep in Btbd9 mutant (MT) mice at 
baseline. Consecutive waveform of representative EEG and EMG from gastrocnemius muscle isolated from the 
right and left legs of (a) wild-type (WT) and (b) MT mice. Integrated EMG power (averaged ZT0-6) during 
(c) wakefulness and (d) NREM sleep was normalized as a ratio to REM sleep in WT (blue bars) and MT (red 
bars) mice. All data are expressed as the means ± SEM (n = 6/group). *p < 0.05, WT versus MT mice. EEG, 
electroencephalogram; EMG, electromyogram; SEM, standard error of the mean.
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patients show a reduction in REM sleep duration and increase in REM sleep latency21. Moreover, the amount 
of slow wave sleep for RLS patients was similar to that for healthy controls, but NREM sleep duration was also 
reduced21. Thus, our results were partially consistent with earlier studies in that we observed decreased amounts 
of REM sleep in the RLS model, yet saw similar basal amounts of NREM sleep for MT and WT mice. Meanwhile, 
basal EMG data for leg muscle showed that MT mice exhibited increased leg muscle activity during NREM 
sleep compared with WT mice. These results support published previously studies that reported a strong linkage 
between BTBD9 and increased PLMS2,22.
Pramipexole, a dopamine D2/D3 receptor agonist, is frequently used to treat RLS and has a sleep disrupting 
effect in mice23. In rats, systemic injection of a D2 receptor agonist induces biphasic effects, wherein low and 
high doses reduce and increase wakefulness, respectively24. Here we found that a high-dose rotigotine treat-
ment indeed increased the amount of wakefulness in both WT and MT mice injected with placebo and serum 
from healthy controls. However, this wake-promoting effect of rotigotine was not observed in mice injected 
with serum from RLS patients who did or did not undergo hemodialysis. Although the explanation for why a 
wake-promoting effect of rotigotine was induced only in mice injected with placebo and healthy control serum 
is unclear, our results suggest that serum from patients with idiopathic and renal RLS may contain substances 
that counteract the arousal effect of rotigotine. These substances may be a factor in the increased muscle activity 
of RLS patients, regardless of the presence of uremic substances. In addition, genotype also contributed to these 
differences in that WT mice tended to show more conspicuous effects of rotigotine compared to MT mice, sug-
gesting that the presence or absence of Btbd9 gene mutations may also be involved in the wake-promoting effect 
of rotigotine. Such mutations could be associated with RLS pathophysiology, a possibility that requires further 
exploration.
We considered that an increase in muscle activity during sleep in MT mice corresponds with PLMS, a major 
RLS symptom. PLMS is also associated with other diseases, but PLMS with and without RLS was significantly 
related to BTBD9 polymorphisms2,22. Here we confirmed that the PLMS findings in the EMG of MT mice were 
similar to those of the putative rat RLS model14.
Figure 3. Effect of rotigotine on the amount of non-rapid eye movement (NREM) sleep in mice injected with 
RLS patient serum. Hourly time course for NREM sleep in wild-type (WT, a–d) and Btbd9 mutant (MT, e–h) 
mice injected with (a and e) placebo, (b and f) serum from healthy subjects (Healthy), (c and g) serum from RLS 
patients with hemodialysis (RLS + HD), and (d and h) serum from RLS patients without hemodialysis (RLS). 
Blue, green, and red circles indicate vehicle, low dose of rotigotine, and high dose of rotigotine, respectively. All 
data are expressed as means ± SEM (n = 5/group). *(Blue) p < 0.05, versus vehicle; *(green) p < 0.05, versus low 
dose of rotigotine; *(red) p < 0.05, versus high dose of rotigotine. SEM, standard error of the mean.
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In EMG taken during NREM sleep, we observed increased leg movement in MT mice injected with serum 
from RLS patients who either had or had not undergone hemodialysis. Rotigotine treatment ameliorated this 
effect, suggesting that the injected serum could contain substances that induced increased muscle activity and 
that the dopaminergic system mediates these effects. Future studies will be needed to detect and identify such 
substances, which could guide the development of novel therapeutics for RLS.
In conclusion, we found that administration of serum from RLS patients increased muscle activity during 
NREM sleep in MT mice with disrupted Btbd9, and this increase in muscle activity was suppressed by rotigotine 
treatment. We also observed that serum from RLS patients could counteract the arousal effect of rotigotine treat-
ment in mice. Our data strongly support previously published reports showing that BTBD9 and the dopaminergic 
system are linked to RLS, and partially clarify the pathophysiological mechanisms of RLS, which may inform new 
approaches for treating RLS.
Materials and Methods
Animals. MT mice were prepared at Gunma University. Mice were kept under pathogen-free barrier condi-
tions, and animal procedures were performed in accordance with institutional and national regulations following 
approval by The Gunma University Animal Care and Experimentation Committee. The commercial embryonic 
stem (ES) cell line (RRE078, BayGenomics) containing a gene trap vector in intron 6 of the Btbd9 gene were 
obtained from the Mutant Mouse Resource & Research Center (MMRRC, UC Davis, CA, USA) and injected 
into blastocysts. These mice were identical to other mice previously described25. Chimeric mice were crossed to 
C57BL/6 mice. Heterozygous mice (Btbd9+/− mice) were further backcrossed to C57BL/6 mice for at least eight 
generations and the resulting heterozygous animals were crossed to produce homozygous mice. Btbd9 MT mice 
were then transferred from Gunma University to Tokushima University for experiments. PCR was used for iden-
tifying the wild-type heterozygous-type and homozygous-type alleles for genotyping. When we used BtbGenome 
primers 1 (Btb F: TTCCTGGTCCTCCTGCTACC) and 2 (Btb R: ACCCGTGGGAAAGCTTAGTG) for identi-
fying the 900 bp wild-type allele. To confirm the presence of the 450 bp trap allele, we used Btb F and trap vector 
primers 3 (Trap R: CCACAACGGGTTCTTCTGTT). We used homozygous mice for all experiments.
The mRNA expression of Btbd9 was confirmed by reverse transcription polymerase chain reaction (RT-PCR). 
Total RNA was purified from mouse cerebrum using Trizol reagent (Invitrogen, Carlsbad, CA, USA), followed 
by DNase digestion and purification using the RNeasy kit (QIAGEN, Valencia, CA, USA). cDNA synthesis was 
Figure 4. Sleep/wake patterns in mice injected with serum from RLS patient treated with rotigotine. Hourly 
averaged sleep/wake amounts in 8-hour periods of light (ZT4-12) and in 12-hour periods of dark (ZT12-24) 
phase for (a) wakefulness, (b) non-rapid eye movement (NREM) sleep, and (c) rapid eye movement (REM) 
sleep. Blue, green and red bars indicate mice injected with vehicle, low dose of rotigotine, and high dose of 
rotigotine, respectively. Dark shading represents wild-type (WT) and light shading indicates Btbd9 mutant 
(MT) mice. All data are expressed as the means ± SEM (n = 6/group). *p < 0.05, **p < 0.01, among vehicle, low 
and high dose of rotigotine. SEM, standard error of the mean.
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performed on total RNA extracted from the mice prefrontal cortex using SuperScript™ VILO™ cDNA Synthesis 
Kit (Thermo Fisher Scientific, Waltham, MA, USA). Then PCR was performed with two primer sets, the forward 
primer located in the exon 4 (Exon5-6F – 5′- AGCTTCTGAACGTCGTGAGG-3′)and reverse primer in the 
exon 5 before the intron containing the gene-trap (Exon5-6R – 5′- TCATCATCAATGGGGTGCCG-3′), the oth-
ers forward primer located in the junction of exon 6 before the intron containing the gene-trap and exon7 after 
this intron (Exon6-7F – 5′-GCCCGTGTCTGCAGGTATAT-3′) and the reverse primer located in the exon 10 
(Exon10R – 5′-TTCGGATGAAGGATGCAGGC-3′). (Supplementary Fig. S1).
Seven-month-old male MT mice and their wild-type littermates were used in this study. Food and water 
were available ad libitum. A 24-hour light-dark cycle (lights on for 12 hours, off for 12 hours) was maintained 
throughout the study (lights on at zeitgeber time [ZT] = 0 at 08:00 am). Room temperature was maintained at 
23 ± 1 °C throughout the experimental period. The study protocol received approval from the Gunma University 
Gene Recombination Experiment Safety Committee and the Animal Experimentation Committee of Tokushima 
University. All experiments involving mice were performed in accordance with Guidelines for the Care and Use 
of Animals approved by the Council of the Physiological Society of Japan.
Sleep recordings and analysis. Mice were anesthetized with a cocktail of ketamine (100 mg/kg) and xyla-
zine (25 mg/kg) for EEG/EMG implantation surgery. Stainless steel miniature screw electrodes were implanted in 
the skull of the mice to record EEGs, and Teflon-coated stainless steel wires were implanted in the gastrocnemius 
muscle of both legs to record EMGs. After a 2-week recovery period, the mice were transferred to plastic cages 
(20 × 24 × 30 cm) in a sound-proof recording room and allowed to habituate for two days. The mice were con-
nected by flexible cables to a polygraph and computer-assisted data acquisition system. EEG/EMG signals were 
captured at 128/500 Hz using a sleep recording system (Vital Recorder, Kissei Comtec, Matsumoto, Japan). Mice 
were also monitored with a video recording system.
Off-line sleep scoring was performed by visual assessment of EEG and EMG activities using the SleepSign 
analysis program (Kissei Comtec, Matsumoto, Japan). Vigilance states were classified for each 10-second period 
as wakefulness, REM sleep, or NREM sleep. The EEG and EMG power spectrum in the period that was scored as 
NREM sleep was calculated by Fast Fourier Transform using the SleepSign analysis program. The EEG delta and 
Figure 5. Effect of rotigotine on the amount of rapid eye movement (REM) sleep in mice injected with serum 
from RLS patients. Hourly time course for REM sleep in wild-type (WT, a–d) and Btbd9 mutant (MT, e–h) mice 
injected with (a and e) placebo, (b and f) serum from healthy subjects (Healthy), (c and g) serum from RLS 
patients with hemodialysis (RLS + HD), and (d and h) serum from RLS patients without hemodialysis (RLS). 
Blue, green and red circles indicate vehicle, low dose of rotigotine, and high dose of rotigotine, respectively. All 
data are expressed as means ± SEM (n = 5/group). *(Blue) p < 0.05, versus vehicle; *(green) p < 0.05, versus low 
dose of rotigotine; *(red) p < 0.05, versus high dose of rotigotine. SEM, standard error of the mean.
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theta frequency bands were set at 0.5–4.0 Hz (SWA) and 4.5–10.5 Hz, respectively. The delta and theta power were 
normalized and described as a percentage of the total power (0.5–30 Hz), and the data were averaged at hourly 
intervals. The EMG total power (50–250 Hz) in each vigilance stage was integrated and normalized as a ratio to 
that of REM sleep. The EEG/EMG data in periods including artificial/electrical noise were excluded from analysis 
after checking the video recording and movement of the mice.
Sleep deprivation. To evaluate sleep homeostasis, mice were sleep-deprived (SD) for 6 hours, between ZT0 
and ZT6, using a small, soft brush to touch the backs of mice that appeared to be somnolent. At ZT6, SD was ter-
minated, and the EEG and EMG were recorded for an 18-hour period of uninterrupted recovery sleep.
Human serum preparation. Serum from 5 healthy subjects and 5 patients with idiopathic RLS and 5 RLS 
patients with secondary to end-stage renal disease was filtered using a Minisart filter (pore size, 0.2 μm; Sartorius 
AG, Göttingen, Germany). After filtration, identical volumes of serum from each subject in the same group 
(healthy subjects, idiopathic RLS patients and patients with RLS and secondary to end-stage renal disease) were 
mixed and the mixtures were used for intraperitoneal (ip) injection into the mice. All 5 RLS patients with second-
ary to end-stage renal disease were received hemodialysis for 4 hours three times a week. The serum was obtained 
from the different patients before hemodialysis. The administration of dopamine agonist was withdrawn for seven 
days. This study was conducted in accordance with the Declaration of Helsinki. Informed consents for partici-
pating this study had obtained from all participants. Research protocol and informed consent were approved by 
Medical Research Ethics Committee of Tokyo Medical University. All experiments were performed in accordance 
with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan.
Pharmacological treatments and injection. Four hours after ip injection with human serum, rotigotine 
was subcutaneously (sc) administered to the mice. Human serum (0.5 ml/30 g mouse; 166.7 ml/kg, ip) or placebo 
(saline) was administered to each animal at ZT0. Rotigotine (1 and 3 mg/kg dissolved in olive oil, Sigma-Aldrich 
Japan, Tokyo, Japan, sc) was administered to each animal at ZT4 (Supplementary Table 1). Sleep data for the 
16 hours following serum administration were captured and analyzed. Each drug/serum was administered in a 
random order with a washout period of 1 week.
Statistics. Results are expressed as the mean ± SEM. The data in Figs 1–5 are normally distributed, while 
the data in Fig. 6 is not normally distributed (tested by Kolmogorov-Smirnov test). The data were analyzed by 
repeated measurement of two-way ANOVA for the hourly time course and the Student’s t-test for comparison 
between two groups in each bin (Fig. 1), Student’s t-test (Fig. 2), repeated measurement of two-way ANOVA 
followed by a Bonferroni/Dunn post-hoc test (Figs 3 and 5), one-way ANOVA followed by a Bonferroni/Dunn 
post-hoc test (Fig. 4), and Kruskal-Wallis test followed by Willcoxon’s test (Fig. 6). For all comparisons, the crite-
rion for significance was p < 0.05 (2-tailed).
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Figure 6. Effect of rotigotine on leg muscle activity during non-rapid eye movement (NREM) sleep in mice 
injected with serum from RLS patients. Normalized EMG in NREM sleep was averaged over 24 hours for wild-
type (WT) and Btbd9 mutant (MT) mice treated with rotigotine after serum injections. Blue, red, and green bars 
indicate serum from healthy subjects (Healthy), RLS patients with hemodialysis (RLS + HD), and RLS patients 
without hemodialysis (RLS), respectively. All data are expressed as the means ± SEM (n = 5/group). *p < 0.05 
versus healthy. SEM, standard error of the mean.
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